SELLAS Life Sciences stock soars 240% on positive cancer trial

SELLAS Life Sciences (NASDAQ:SLS) shares rose 240% after reporting positive Phase 3 trial results for its cancer vaccine, GPS. The trial met its primary endpoint, showing a 41% reduction in death risk and improved median survival. The company plans to discuss an accelerated FDA filing strategy. GPS was well-tolerated with mild to moderate side effects.

Original reporting
Published Nov 17, 2026, 1:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$SLS
Bullish
high confidence
Mentioned
$SLS
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SLSBullishHigh
01

Why it matters

The disclosed OS benefit (hazard ratio 0.59, p-value 0.035) plus a stated intent to pursue an accelerated filing strategy and prepare a BLA in 1H 2027 are likely to increase perceived regulatory and commercialization probability, supporting a higher valuation multiple.

02

Market read

Traders can act on a fresh pivotal-trial catalyst with explicit regulatory next steps, which typically changes near-term positioning and options pricing for biotech risk.

03

What to watch

The article does not provide details on secondary endpoints, subgroup effects, or manufacturing/commercial readiness, which can materially affect valuation even after OS success.

Relevance 9/10Novelty 9/10Timing: immediate post-topline reaction, with next catalysts tied to FDA discussions and 1H 2027 BLA preparations

Background

SELLAS is advancing galinpepimut-S (GPS) in acute myeloid leukemia; the REGAL Phase 3 trial is described as pivotal and focused on maintenance monotherapy in patients in second or later complete remission who cannot undergo allogeneic stem cell transplantation.

Company-level read

Ticker impact

$SLSBullishHigh confidence
Context

SELLAS shares surged after announcing positive topline Phase 3 REGAL results for galinpepimut-S, including OS benefit and FDA accelerated filing plans.

Expected impact

Likely upward bias as markets price higher odds of accelerated approval, with potential pullbacks on dilution/valuation concerns and as secondary endpoints and safety details mature.

Evidence & confidence

The article reports primary endpoint success (OS, hazard ratio, p-value) plus a stated plan to meet FDA and prepare a BLA in 1H 2027, which are direct catalysts for biotech risk-reward repricing.

Market effects

Reinforces risk-on sentiment for AML immunotherapy vaccine approaches and can lift peer sentiment around immunotherapeutic strategies, though impact is company-specific.

Limited broader regional spillover expected beyond US biotech sentiment given the single-name catalyst.

Moderate global relevance for oncology trial read-through, but the trading signal is primarily US-listed biotech-specific.

Counterpoint

A single topline primary endpoint can be over-discounted; secondary endpoints, durability, and any later safety signals could temper the initial enthusiasm.

Key entities

  • SELLAS Life Sciences Group

    NASDAQ-listed biotech whose REGAL Phase 3 topline results for galinpepimut-S drove a sharp share surge.

  • Galinpepimut-S (GPS)

    Immunotherapeutic cancer vaccine evaluated as maintenance monotherapy in the REGAL trial.

  • U.S. Food and Drug Administration (FDA)

    Planned meeting to discuss accelerated filing strategy for a potential BLA submission.

Related articles

$SLSHighAI 9/10

Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial – Firm Eyes FDA Filing In First Half Of 2027

Sellas Life Sciences (SLS) reported that its experimental cancer vaccine, GPS, met its primary goal in a Phase 3 trial, reducing the risk of death by 41% in AML patients. The trial showed a median overall survival of 24 months vs. 14.7 months for the control group. The company plans to file for FDA approval in the first half of 2027. SLS shares rose 7.1% pre-market before trading was halted.

$SLSMedAI 8/10

Sellas' Cancer Vaccine Cuts Death Risk By 41% In Phase 3 Leukemia Trial

SELLAS Life Sciences (SLS) reported that its cancer vaccine, galinpepimut-S, met the primary survival endpoint in a Phase 3 trial for acute myeloid leukemia. The vaccine reduced death risk by 41% compared to standard treatment, with median survival of 24 months versus 14.7 months. The company plans to discuss FDA filing strategy in 2027. SLS shares rose 7.10% in pre-market trading.

$SLSHighAI 9/10

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Ov

SELLAS Life Sciences (NASDAQ: SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, GPS, showing a 41% reduction in death risk and median OS of 24.0 months vs. 14.7 months for standard treatment. The company plans to meet with the FDA to discuss regulatory path. GPS was well-tolerated with no new safety signals. SELLAS will host a webcast to discuss results and next steps.

$SLSMedAI 8/10

SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a…

SELLAS Life Sciences Group, Inc. (SLS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid

$NVDAMed

Stocks making the biggest moves premarket: Disney, Home Depot, Nvidia & more

Coherent, Applied Optoelectronics, and Lumentum shares rose 11%, 8.6%, and 5.6% respectively, following a Reuters report on potential U.S. restrictions on Chinese data center equipment. Sellas Life Sciences shares gained over 7% after positive trial results for its cancer vaccine. Nvidia shares rose 1% ahead of earnings, despite a 25% stake reduction in Intel. Home Depot shares fell 2% with a CEO transition.